Ken Griffin Tarsus Pharmaceuticals, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 12,100 shares of TARS stock, worth $327,184. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,100
Previous 12,700
4.72%
Holding current value
$327,184
Previous $257,000
70.82%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding TARS
# of Institutions
165Shares Held
40.5MCall Options Held
190KPut Options Held
92.9K-
Rtw Investments, LP New York, NY3.27MShares$88.5 Million1.91% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.86MShares$77.4 Million3.9% of portfolio
-
Black Rock Inc. New York, NY2.65MShares$71.7 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.4MShares$64.9 Million0.01% of portfolio
-
Tang Capital Management LLC San Diego, CA2.25MShares$61 Million9.98% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $721M
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...